Open access · CC-BY
via OpenAlex
Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influx
Kevin A. Strauss, Joan Brumbaugh, Alana Duffy, Bridget Wardley, Donna Robinson, Christine Hendrickson, Silvia Tortorelli, Ann B. Moser, Erik G. Puffenberger, Nicholas L. Rider, D. Holmes Morton
Molecular Genetics and Metabolism · 2011 · ▲ 91 citations
Abstract
Striatal degeneration from glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type 1, GA1) is associated with cerebral formation and entrapment of glutaryl-CoA and its derivatives that depend on cerebral lysine influx. In 2006 we designed a lysine-free study formula enriched with arginine to selectively block lysine transport across cerebral endothelia and thereby limit glutaryl-CoA production by brain. Between 2006 and present, we treated twelve consecutive children with study formula (LYSx group) while holding all other treatment practices constant. Clinical and biochemical outcomes were compared to 25 GA1 patients (PROx group) treated between 1995 and 2005 with natural protein restriction (dietary lysine/arginine ratio of 1.7±0.3 mg:mg). We used published kinetic parameters of the y+and LAT1 blood-brain barrier transporters to model the influx of amino acids into the brain. Arginine fortification to achieve a mean dietary lysine/arginine ratio of 0.7±0.2 mg:mg was neuroprotective. All 12 LYSx patients are physically and neurologically healthy after 28 aggregate patient-years of follow up (current ages 28±21 months) and there were no adverse events related to formula use. This represents a 36% reduction of neurological risk (95% confidence interval 14-52%, p=0.018) that we can directly attribute to altered amino acid intake. During the first year of life, 20% lower lysine intake and two-fold higher arginine intake by LYSx patients were associated with 50% lower plasma lysine, 3-fold lower plasma lysine/arginine concentration ratio, 42% lower mean calculated cerebral lysine influx, 54% higher calculated cerebral arginine influx, 15-26% higher calculated cerebral influx of several anaplerotic precursors (isoleucine, threonine, methionine, and leucine), 50% less 3-hydroxyglutarate excretion, and a 3-fold lower hospitalization rate (0.8 versus 2.3 hospitalizations per patient per year). The relationship between arginine fortification and plasma lysine indicates that transport competition exists at both cerebrovascular and gastrointestinal barriers, suggesting their co-administration is key to efficacy. Monitoring the ratio between lysine and arginine in diet and plasma may prove a useful strategy for treating children with GA1.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.ymgme.2011.07.003
- Canonical
- link ↗
- Fetched
- 2026-09-16 MST
Cite this
APA
Strauss, K.A., Brumbaugh, J., Duffy, A., Wardley, B., Robinson, D., Hendrickson, C., Tortorelli, S., Moser, A.B., Puffenberger, E.G., Rider, N.L., & Morton, D.H. (2011). Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influx. <em>Molecular Genetics and Metabolism</em>. https://doi.org/10.1016/j.ymgme.2011.07.003
Vancouver
Strauss KA, Brumbaugh J, Duffy A, Wardley B, Robinson D, Hendrickson C, et al. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influx. Molecular Genetics and Metabolism. 2011. doi:10.1016/j.ymgme.2011.07.003.
BibTeX
@article{kevin2011Safety,
title = {Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influx},
author = {Kevin A. Strauss and Joan Brumbaugh and Alana Duffy and Bridget Wardley and Donna Robinson and Christine Hendrickson and Silvia Tortorelli and Ann B. Moser and Erik G. Puffenberger and Nicholas L. Rider and D. Holmes Morton},
journal = {Molecular Genetics and Metabolism},
year = {2011},
doi = {10.1016/j.ymgme.2011.07.003},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
New England Journal of Medicine 2006
Citation only
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Ove Andersen 2026
Open access · US-GOV
Methods for Assessing Nutrition, Inflammation, Kidney Function, Aging, Body Composition, and Hydration Among Older Patients - An Observational Study (MIKADO)
Nature Reviews Drug Discovery 2020
Open access · OA
Reversing inflammaging
Trends in Endocrinology and Metabolism 2016
Open access · OA
Inflammaging and ‘Garb-aging’
Journal of the American Heart Association 2021
Open access · CC-BY
Identification of Frailty Using a Claims‐Based Frailty Index in the CoreValve Studies: Findings from the EXTEND‐FRAILTY Study
The Japanese Journal of SURGICAL METABOLISM and NUTRITION 2018
Open access · OA